RCEL
AVITA Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$11.02
−1.78%Sep 16, 2026, 17:44 UTC
AVITA Medical raised its 2026 revenue guidance to $86 million-$89 million from $80 million-$85 million at the Morgan Stanley 24th Annual Global Healthcare Conference.
Source:Aug 18, 2026, 11:45 UTC
AVITA Medical announced positive study results for its PermeaDerm product, demonstrating a 70% economic advantage over allograft and comparable clinical outcomes.
Aug 7, 2026, 06:54 UTC
AVITA Medical, Inc. held its Q2 2026 earnings call on August 6, 2026.
Jun 8, 2026, 00:00 UTC
AVITA Medical issued a warrant to Perceptive Credit Holdings V, LP as part of a credit agreement, granting rights to purchase up to 500,000 shares of common stock.